From savmiass@planet.net.hk  Tue Dec 24 14:36:57 2002
Return-Path: <savmiass@planet.net.hk>
Received: from mx1.FreeBSD.org (mx1.freebsd.org [216.136.204.125])
	by hub.freebsd.org (Postfix) with ESMTP id EE9E937B405
	for <bug-followup@freebsd.org>; Tue, 24 Dec 2002 14:36:57 -0800 (PST)
Received: from sand13.gxn.net (sand13.gxn.net [195.147.249.206])
	by mx1.FreeBSD.org (Postfix) with ESMTP id 9C54643EA9
	for <bug-followup@freebsd.org>; Tue, 24 Dec 2002 14:36:56 -0800 (PST)
	(envelope-from savmiass@planet.net.hk)
Received: from mail.euromarine-ltd.com ([195.147.8.226] helo=server.euromarine-ltd.com)
	by sand13.gxn.net with esmtp (Exim 3.36 #3)
	id 18QrU4-0002vM-00
	for bug-followup@freebsd.org; Tue, 24 Dec 2002 16:00:47 +0000
Received: from mx1.nameplanet.mail2world.com (200.215.17.134) by server.euromarine-ltd.com (Worldmail 1.3.167); 20 Dec 2002 15:20:44 +0000
Message-Id: <000064b0269d$00002d5f$000032db@bodycare.com.hk>
Date: Fri, 20 Dec 2002 07:03:27 -2000
From: "Liz Carter" <savmiass@planet.net.hk>
To: <gene@beaux.atwc.teradyne.com>
Cc: <perfdata@netzero.net>, <seniho@legogo.org>,
	<dalptekin@earthlink.net>, <linds_d@hotmail.com>, <lcstaton@aol.com>,
	<amy12278@yahoo.com>, <ci-111784@mail15.calypso.net>,
	<triplehsuply@vnet.net>, <bug-followup@freebsd.org>,
	<ag-landy@inreach.com>, <viboeldi@aol.com>, <docrlc@aol.com>,
	<gwilkins1@hotmail.com>
Subject: Listening While he is14557

>Number:         46519
>Category:       junk
>Synopsis:       Listening While he is14557
>Confidential:   no
>Severity:       serious
>Priority:       medium
>Responsible:    gnats-admin
>State:          closed
>Quarter:        
>Keywords:       
>Date-Required:  
>Class:          sw-bug
>Submitter-Id:   current-users
>Arrival-Date:   Tue Dec 24 14:40:00 PST 2002
>Closed-Date:    Mon Dec 30 01:14:25 PST 2002
>Last-Modified:  Mon Dec 30 01:14:25 PST 2002
>Originator:     
>Release:        
>Organization:
>Environment:
>Description:
 STOCK ALERT 
 
 RJV Networks, Inc. (OTC BB: RJNV)
 
 TARGET Price $4 -to- $6 in January 2003
 
 Tonight: RJNV holds exclusive licenses to state-of-the-art
 bio-technology developed at University of Michigan and the
 Cancer Control Agency of B.C. that experts are using to
 develop therapies believed to be capable of treating most
 cancers.  
 
 Through an acquisition of BioKinetix Research, Inc.
 (currently underway), RJVN is rapidly completing the
 development of a therapy for cancer that will make a
 lasting impression on the multibillion dollar bio-tech
 industry. Read more about this exciting up and comer below.
 
 
 -----------------------------------------------------------
 Company Name----------RJV Networks, Inc.
 Symbol----------------RJVN
 Current Price---------$0.26
 52 Week High----------$2.10
 52 Week Low-----------$0.26
 Target $4 -to- $6
  
 
 Investment Highlights:
 
 RJVN projects it will be able to treat most cancers with
 its combined targeted therapy treatment which is based upon
 an astounding discovery by a molecular biologist at the
 Univ. of Michigan - The causal link to breast and most
 other malignancies and cancers in the protein Mammastatin.
   
 RJVN has developed a series of cancer treatment therapies
 which utilize pan-cancer market antibodies. Antibody
 therapies do not create chemical toxicity and, as such,
 are fast tracked through the regulatory approval process. 
 Using this approach, RJVN is targeted to enter testing for
 its products in six months. 
   
 RJVN's combination of two leading, well known technologies
 previously announced by BioCurex and InNexus Corp along
 with RJVN's key MAb protein replicating technology has
 allowed the Company to create a series of patented
 therapeutic products that many molecular biologists believe
 will treat most cancers. RJVN's R&D and Management are led
 by Dr. John Todd, Dr. Charles Morgan (a world renowned
 molecular biologist and 5 other industry leading Dr's all
 with several years experience in bio-tech development.  
 
 About the Company:
 
 RJVN (through BioKinetix Research, Inc.) was formed after
 Dr. John Todd, a very well known and respected oncological
 surgeon from BC, approached us with the story of an
 astounding discovery that had been made by molecular
 biologists at the University of Michigan. This discovery
 was believed to be the causal link to breast cancer, the
 link is a medium sized (53KD) protein called Mammastatin. 
 The evidence is that Mammastatin is the agent that, when
 present, prevents the development and growth of malignant
 breast tumors. Mammastatin is freely expressed by the
 epithelial cells in the breast and as such acts as a
 natural contra-agent to malignant development. Women who
 develop breast cancer have NO or extremely low levels of
 Mammastatin in their system. After testing hundreds of
 women, no woman with normal Mammastatin levels has
 developed breast cancer
 
 Dr. John Todd in conjunction with the Cancer Control
 Agency of B.C. conducted compassionate trials on several
 terminally ill patients (authorized by Health Canada)
 with a Mammastatin replacement program the results of
 which thoroughly convinced Dr. Todd of the direct link.
 The challenge existed from the fact that proteins are
 extremely difficult to sequence (replicate). Mammastatin
 has over 400 amino-acids in it's chain, and, even if
 successful in sequencing, the synthetic replication is
 even more difficult. Finally the delivery of a protein,
 natural or synthetic, will now have to face the natural
 breakdown of the chain as it circulates through the body.
 
 Dr. Charles Morgan is a world-renowned molecular biologist
 who has proposed an alternative approach to this problem. 
 He is convinced, and several well known molecular
 biologists agree with him, that he can mimic the active
 component of the Mammastatin protein through the production
 of an anti-idiotypic monoclonal antibody (MAb). These MAbs
 are stable, target specific and will in all measure act
 like the native Mammastatin. To dramatically enhance
 the bio-activity of these anti-idiotypic monoclonal
 antibodies, RJNV will create Superantibodies through
 the use of InNexus' Super Antibody platform technology
 (see news for OTC BB: BOCX about this technology). This
 technology allows the cross linking of antibodies to
 boost their potency and resiliency.
 
 As a result of the scientific approach implemented by
 RJNV's BioKinetix (acquisition underway), the company
 has negotiated a license from BioCurex OTC BB: BOCX to
 develop therapeutic products based on their pan-cancer
 marker antibodies. The combination of these two
 technologies gives RJVN the potential to create a series
 of therapeutic products that will treat most cancers.
 
 Antibody therapies do not create chemical toxicity and,
 as such, are fast tracked through the regulatory approval
 process. Using this approach, RJVN is targeted to enter
 testing for its products in six months.
 
 Industry Potential:
 
 The potential market for RJVN's cancer treatment therapies
 far outstrips any reasonable estimate to be made at this
 time. As the Company implements its technology upon
 entering the market test phase, we expect a large bio-tech
 or pharmaceutical mfr. to acquire the Company for several
 hundred million.
 
 Due to the Companies ability to fast track, beginning
 clinical trials of its revolutionary cancer treatment in
 early 2003E, exposure of its initial success will spread
 quickly.  
 
 Conclusion:
 
 The Company will be participating in a road-show in January
 and February of 2003, meeting with several institutional
 brokerage houses in San Francisco, New York, and other
 major metro areas to showcase their technology. We expect
 many pension fund managers to begin positioning the stock
 in their portfolios sometime in Q1/2003 and Q2/2003.
 
 The stock is highly undervalued currently due to the
 fact that there has been no P/R done on the Company.
 Mass direct mail, investment club profiles and other
 P/R related activities are beginning with the issuance
 of this newsletter. We expect the stock to appreciate
 significantly over the next 20-trading days.
 
 TARGET Price $4 -to- $6 in January 2003
 
 
 ****************** Special Offer ******************
 If you would like to be included in our mailing list,
 you will receive a 10 day free trial to a web site
 with real-time Level II quotes, research reports
 from major providers, analyst upgrades/downgrade info,
 Bulletin Board Promotion / Syndication Calendar (1st
 of its kind), and access to our trading chat rooms and
 several message boards with real live professionals.
 Just click on the link below to send us an email, be
 sure the subject line reads "Opt-in" and you will me
 immediately added.
 MailTo:cellbrat@excite.com?Subject=Opt-in
 
 
 ****Disclaimer 
 Information within this email contains "forward looking
 statements" within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21B of the Securities
 Exchange Act of 1934. Any statements that express or
 involve discussions with respect to predictions,
 expectations, beliefs, plans, projections, objectives,
 goals, assumptions or future events or performance are
 not statements of historical fact and may be "forward
 looking statements."
 
 Forward looking statements are based on expectations,
 estimates and projections at the time the statements
 are made that involve a number of risks and uncertainties
 which could cause actual results or events to differ
 materially from those presently anticipated. The words: 
 "expects," "will," "projects," "Foresee," "anticipates,"
 "estimates," "believes," "understands," or that by
 statements indicating certain actions "may," Could," or
 "might occur. All information provided within this email
 pertaining to investing, stocks, securities must be
 understood as information provided and not investment
 advice. Emerging Equity Alert advises all readers and
 subscribers to seek advice from a registered professional
 securities representative before deciding to trade in
 stocks featured within this email. None of the material
 within this report shall be construed as any kind of
 investment advice.
 
 In compliance with the Securities Act of 1933, Section
 17(b), Emerging Stock Alert discloses the receipt of
 125,000 unrestricted shares of RJVN from a third party
 for the publication of this report. Be aware of an inherent
 conflict of interest resulting from such compensation due
 to our intent to profit from the liquidation of these
 shares. Shares may be sold at any time, even after
 positive statements have been made regarding the above
 company. All factual information in this report was
 gathered from public sources, including but not limited
 to SEC filings, Company Press Releases, and Market Guide. 
 Emerging Equity Alert believes this information to be
 reliable but can make no guarantee as to its accuracy
 or completeness. Use of the material within this email
 constitutes your acceptance of these terms. 
 
 
 ********Advertising Disclaimer********
 We as an advertising company have received only a monetary
 payment for this mailing service. We hold no stocks and
 have no personal interest whatsoever in this company.
 **************************************
 
 
 Remove instructions:
 This message has been sent to you in compliance with our
 strict anti-abuse regulations. We will continue to bring
 you valuable offers on the products and services that
 interest you most. If you do not wish to receive any
 further mailings, please click on this link to send us
 an email to MailTo:melanie4447@yahoo.com?Subject=no-more .
 Be sure that "no-more" appears in the subject line. You
 can be assured that you will no longer receive email from
 us. We respect all removal requests. This message is an
 advertisement. Copyright 2000, 2001, 2002 all rights
 reserved.
 
>How-To-Repeat:
>Fix:
>Release-Note:
>Audit-Trail:
State-Changed-From-To: open->closed 
State-Changed-By: keramida 
State-Changed-When: Mon Dec 30 01:14:13 PST 2002 
State-Changed-Why:  
Junk / spam. 

http://www.freebsd.org/cgi/query-pr.cgi?pr=46519 
>Unformatted:
